Trial Outcomes & Findings for Wearable Vibration Device to Prevent Bone Loss in Postmenopausal Women--Aim 2 (NCT NCT03688282)

NCT ID: NCT03688282

Last Updated: 2021-04-27

Results Overview

Percent change in NTX, a biomarker of bone loss activity measured in the blood. Percent change in NTX was determined from Baseline (pre-treatment) to 30-minutes post-treatment for the sham treatment and the active treatments. The difference in percent change was then compared between active and sham treatments.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

18 participants

Primary outcome timeframe

Baseline and 30 minutes after completing the 30-minute treatment session

Results posted on

2021-04-27

Participant Flow

Participant milestones

Participant milestones
Measure
Sham & 30 Minute Treatment
Visit 1: Device will be worn but not turned on. Wearable vibration belt: The device is worn, a wearable vibration belt, for a specified time. This will provide vibration starting at the hips. Visit 2: Device will be worn and turned on for 30 minute treatment. Wearable vibration belt: The device is worn, a wearable vibration belt, for a specified time. This will provide vibration starting at the hips.
Sham Treatment for 30 Minutes
STARTED
18
Sham Treatment for 30 Minutes
COMPLETED
17
Sham Treatment for 30 Minutes
NOT COMPLETED
1
Washout (7 Days)
STARTED
17
Washout (7 Days)
COMPLETED
17
Washout (7 Days)
NOT COMPLETED
0
Active Treatment for 30 Minutes
STARTED
17
Active Treatment for 30 Minutes
COMPLETED
17
Active Treatment for 30 Minutes
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Wearable Vibration Device to Prevent Bone Loss in Postmenopausal Women--Aim 2

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Sham & 30 Minute Treatment
n=18 Participants
Visit 1: Device will be worn but not turned on for 30 minute treatment. Wearable vibration belt: The device is worn, a wearable vibration belt, for a specified time. This will provide vibration starting at the hips. Visit 2: Device will be worn and turned on for 30 minute treatment. Wearable vibration belt: The device is worn, a wearable vibration belt, for a specified time. This will provide vibration starting at the hips.
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
18 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Age, Continuous
54.41 years
STANDARD_DEVIATION 4.77 • n=99 Participants
Sex: Female, Male
Female
18 Participants
n=99 Participants
Sex: Female, Male
Male
0 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
18 Participants
n=99 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=99 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=99 Participants
Race (NIH/OMB)
White
16 Participants
n=99 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=99 Participants
Region of Enrollment
United States
18 Participants
n=99 Participants

PRIMARY outcome

Timeframe: Baseline and 30 minutes after completing the 30-minute treatment session

Population: All subjects that completed both treatment sessions

Percent change in NTX, a biomarker of bone loss activity measured in the blood. Percent change in NTX was determined from Baseline (pre-treatment) to 30-minutes post-treatment for the sham treatment and the active treatments. The difference in percent change was then compared between active and sham treatments.

Outcome measures

Outcome measures
Measure
Sham Treatment Session
n=17 Participants
Device will be worn but not turned on (does not deliver the active treatment) for 30 minute treatment session.
Active Treatment Session
n=17 Participants
Device will be worn and turned on (delivers the active treatment) for 30 minute treatment session.
Percent Change in Blood-based Biomarker of Bone Loss
8.8 Percent change
Standard Deviation 7.6
-5.4 Percent change
Standard Deviation 8.8

Adverse Events

Sham Treatment Session

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Active Treatment Session

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Vice President of Research and Development

TheraNova

Phone: 415-926-8616

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60